Top 10 Companies in the (S)-1-Aminotetraline (CAS 21880-87-5) Market (2026): Market Leaders Powering Global Pharmaceutical Synthesis

MARKET INSIGHTS

Global (S)-1-Aminotetraline (CAS 21880-87-5) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(S)-1-Aminotetraline, also known as (S)-(-)-1,2,3,4-tetrahydro-1-naphthalenamine, is a chiral amine compound with the CAS number 21880-87-5. It serves as a critical building block and intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting the central nervous system. Its stereospecific configuration makes it especially valuable in the development of dopaminergic and serotonergic receptor ligands, as well as in the preparation of enantiopure drug candidates requiring a tetralin scaffold.

The market is witnessing steady growth driven by rising demand for chiral intermediates in pharmaceutical research and development, increasing focus on CNS drug discovery, and the expanding pipeline of neurological therapeutics globally. Furthermore, the growing adoption of asymmetric synthesis techniques and heightened regulatory emphasis on enantiopure active pharmaceutical ingredients (APIs) continue to reinforce demand. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Combi‑Blocks, among other fine chemical manufacturers catering to research and commercial‑scale requirements.

(S)-1-Aminotetraline (CAS 21880-87-5) Market – View in Detailed Research Report

Top 10 Companies Driving the Market

1. Biosynth AG (Switzerland)

Headquarters: Basel, Switzerland
Key Offering: Custom synthesis of chiral intermediates for clinical development

Biosynth AG has built a reputation for delivering high‑purity, enantiopure materials to early‑stage pharmaceutical companies. Its state‑of‑the‑art asymmetric hydrogenation platform consistently achieves ee values above 99%, enabling rapid progression of lead candidates through pre‑clinical studies.

Sustainability & Growth Initiatives: Investment in renewable energy for production facilities and a closed‑loop waste management system reduce the environmental footprint of each batch.

• Dedicated R&D team focused on expanding the tetralin scaffold library.
• Partnerships with academic institutions for joint development projects.
• Strategic expansion into Asian markets to support emerging biopharma hubs.

2. Enamine LLC (Ukraine)

Headquarters: Kyiv, Ukraine
Key Offering: C‑GMP compliant chiral intermediates for drug discovery

Enamine’s robust production infrastructure supports a wide range of enantiopure compounds. Its streamlined supply chain allows rapid turnaround for milligram‑to‑gram scale orders, which is essential for early‑stage research labs.

Sustainability & Growth Initiatives: Implementation of ISO 14001 environmental management and adoption of green solvents in synthesis routes.

• Expansion of the synthetic portfolio to include isoquinoline derivatives.
• Collaborations with CROs to provide custom synthesis services.
• Focus on continuous process development for scalability.

3. Capot Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Large‑scale production of (S)-1‑Aminotetraline with >98% ee

Capot Chemical operates one of the largest asymmetric hydrogenation plants in Asia, ensuring consistent supply for global pharma clients. The company’s emphasis on process robustness and quality control secures a reliable stream of high‑purity intermediates.

Sustainability & Growth Initiatives: Integration of solar power into manufacturing and a zero‑waste policy for solvent recovery.

• Investment in automated synthesis platforms to increase throughput.
• Expansion of the product line to include enantiopure alkylamines.
• Strengthening of supply‑chain partnerships with key API manufacturers.

4. Hairui Chemical Co., Ltd. (China)

Headquarters: Shenzhen, China
Key Offering: Custom chiral synthesis for early‑stage drug discovery

Hairui Chemical specializes in delivering small‑batch, high‑purity chiral intermediates. Its flexible production model caters to the dynamic needs of biotech firms exploring novel CNS targets.

Sustainability & Growth Initiatives: Adoption of green chemistry principles and a commitment to reducing carbon emissions.

• Rapid scale‑up capabilities for pilot‑scale projects.
• Collaborations with universities for catalyst development.
• Expansion of the synthetic library to include heteroaryl amines.

5. Shanghai Trustin Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: C‑GMP compliant (S)-1‑Aminotetraline for clinical trials

Trustin Chemical’s stringent quality framework ensures compliance with global regulatory standards. Its batch‑to‑batch consistency is critical for pharmaceutical companies conducting early‑phase studies.

Sustainability & Growth Initiatives: Implementation of energy‑efficient distillation units and waste‑water recycling.

• Development of a scalable resolution process for the (S)‑enantiomer.
• Strategic alliances with contract manufacturers in Europe.
• Focus on reducing production costs through process optimization.

6. Ningbo Inno Pharmchem Co., Ltd. (China)

Headquarters: Ningbo, China
Key Offering: High‑purity (S)-1‑Aminotetraline for API synthesis

Inno Pharmchem leverages advanced chiral chromatography techniques to achieve exceptional ee values. The company’s flexible order volumes accommodate both research labs and larger manufacturing partners.

Sustainability & Growth Initiatives: Use of biodegradable solvents and a closed‑loop waste system.

• Expansion of the synthetic portfolio to include chiral amides.
• Partnerships with CROs to support early‑stage development.
• Continuous improvement of purification protocols.

7. Finetech Industry Limited (China)

Headquarters: Guangzhou, China
Key Offering: Custom synthesis of chiral amines for drug discovery

Finetech’s modular production approach allows rapid iteration of new synthetic routes. Its focus on precision chemistry supports the creation of novel CNS ligands with high selectivity.

Sustainability & Growth Initiatives: Commitment to reducing hazardous waste and improving energy efficiency.

• Development of biocatalytic routes for amine synthesis.
• Collaboration with biotech firms to tailor synthesis for specific targets.
• Investment in high‑throughput screening of synthetic routes.

8. AstaTech, Inc. (USA)

Headquarters: San Diego, USA
Key Offering: Enantiopure (S)-1‑Aminotetraline for research and commercial use

AstaTech’s emphasis on quality and regulatory compliance makes it a trusted supplier for U.S. pharmaceutical companies. The firm’s dedicated QA team ensures that each batch meets stringent purity criteria.

Sustainability & Growth Initiatives: Adoption of green solvents and a focus on reducing water usage.

• Expansion of the product line to include chiral building blocks for CNS drugs.
• Collaboration with academic research groups for early‑stage projects.
• Investment in automated synthesis platforms for scalability.

9. Tokyo Chemical Industry Co., Ltd. (Japan)

Headquarters: Tokyo, Japan
Key Offering: High‑purity chiral intermediates for API development

Tokyo Chemical Industry’s reputation for precision chemistry supports the development of complex CNS therapeutics. Its process engineering expertise ensures consistent ee values across large batches.

Sustainability & Growth Initiatives: Implementation of energy‑saving technologies and waste‑minimization strategies.

• Development of scalable resolution processes.
• Partnerships with Japanese pharmaceutical firms to support domestic pipelines.
• Focus on reducing solvent consumption.

10. Apollo Scientific Ltd (UK)

Headquarters: Cambridge, UK
Key Offering: Custom synthesis of (S)-1‑Aminotetraline for research and early‑stage development

Apollo Scientific’s flexible production model accommodates the variable demands of biotech and academic labs. The company’s commitment to quality and regulatory compliance ensures reliability for early‑stage drug discovery.

Sustainability & Growth Initiatives: Adoption of green chemistry principles and a focus on waste reduction.

• Expansion of the synthetic portfolio to include heterocyclic amines.
• Collaboration with CROs for early‑stage synthesis projects.
• Investment in process automation for increased throughput.

Download FREE Sample Report

Get Full Report Here

Market Outlook

Over the next decade, the demand for chiral intermediates in CNS drug development is likely to strengthen. The shift toward precision medicine, coupled with an expanding pipeline of dopaminergic and serotonergic agents, will sustain the need for high‑purity (S)-1‑Aminotetraline. Manufacturers that invest in scalable, green synthesis routes will capture a larger share of the market, as regulatory bodies increasingly require detailed stereochemical characterization.

Emerging Trends

• Adoption of continuous flow chemistry to streamline asymmetric synthesis and reduce batch variability.
• Integration of biocatalysis for the production of chiral amines, offering lower environmental impact and higher selectivity.
• Growth of personalized medicine initiatives, driving demand for small‑molecule therapeutics with high stereoselectivity.
• Increasing collaboration between academic research groups and fine‑chemical manufacturers to accelerate the translation of novel CNS ligands into clinical candidates.